Kissei's existing business flat but R&D pipeline should lead to growth in
Kissei Pharmaceuticals of Japan recently hosted a visit from analysts atHSBC which saw the company in confident mood regarding the state of its research pipeline. This would appear to represent good news for the firm, especially given its current position, as its existing business has not been overly-impressive of late.
The analysts note that Kissei is still heavily dependent on revenues from the domestic market and most of its leading products are mature. However, news flow is expected to be good over the next year and the company's present performance is ahead of forecasts.
The most advanced product for the company involves a new use of its antihistamine Rizaben (tranilast), which is being developed for the prevention of restenosis after percutaneous transluminal coronary angioplasty (PTCA). The Japanese Ministry of Health and Welfare has asked for data on Rizaben's efficacy in preventing cardiovascular events and Kissei intends to supply this from a trial being conducted overseas by SmithKline Beecham, which is due to be completed in 2001.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze